GlassScriptPhysician profile
Ann H Snyder
NPI 1104990878
$4,413.14
in general payments reported to CMS, 2019-2025
51 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $426 · 2021: $676 · 2022: $369 · 2023: $724 · 2024: $1,029 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.97 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $358.66 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $356.43 | 2021-2025 | Freestyle Libre 3, Id Now Instrument, Jot Dx |
| Lilly USA, LLC | $355.60 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $309.38 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $299.22 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $268.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $186.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $179.34 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $124.66 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $100.70 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $98.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.19 | 2019-2023 | Trintellix |
| Dexcom, INC. | $88.68 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $79.91 | 2022-2025 | Veozah, Myrbetriq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.